Clinical Context
A typical patient is a postmenopausal woman with hormone receptor–positive, metastatic or locally advanced estrogen receptor–positive breast cancer who requires endocrine therapy after progression on prior anti-estrogen agents. The patient presents to an oncology infusion clinic for administration of intramuscular fulvestrant, billed with J9394 (fulvestrant, 25 mg, specific manufacturer not therapeutically equivalent to J9395). Clinical workflow: the medical oncologist documents indication, prior therapy, and weight/administration instructions in the electronic medical record; the oncology nurse verifies allergies, obtains informed consent for medication administration, confirms appropriate lab results (if required), and prepares the dose per pharmacy. Pharmacy dispenses the single-use prefilled syringe or vial labeled with J9394, and the nurse administers the intramuscular injection (usually into the gluteal muscle) while monitoring the patient for immediate adverse reactions for 15–30 minutes. Documentation includes the drug name and manufacturer, NDC, dose (number of 25 mg units billed), lot number, site of injection, route, date/time, and any concurrent medications or supportive care. Billing uses J9394 with appropriate diagnosis linkage to the oncology indication and may append a modifier if applicable (e.g., JW for discarded drug, QX for CRNA service under qualified supervision). Typical site of service is an outpatient hospital infusion center, physician office infusion suite, or freestanding oncology clinic. Payors commonly involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare for coverage and claims processing.